ReviewMedical science monitor : international medical journal of experimental and clinical research2026
Mechanism, Dose, and Administration of Dexmedetomidine in Managing Visceral Pain Associated With Surgery: A Narrative Review.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral pain is often refractory and debilitating. Effective therapy for visceral pain remains undetermined or even elusive. Recently, dexmedetomidine (DEX) has been found to be promising as an adjuvant in relieving visceral pain. DEX, a highly selective alpha-2 adrenoreceptor agonist, is increasingly used during the perioperative period. DEX induces sedation, analgesia, anxiolysis, sympathetic tone inhibition, and intestinal barrier protection. It has shown favorable analgesic effects in clinical and animal studies and is a useful adjuvant treatment for visceral pain. It can be delivered via intravenous injections, intraspinal administration, intraperitoneal spraying, or other routes, and it exerts antinociceptive effects on visceral pain. This article reviews the mechanisms, dose, and modes of administration of dexmedetomidine in managing visceral pain associated with surgery. Moreover, we highlight the clinical evidence of DEX on visceral pain therapy in recent years. We also address the various protocols and routes for using DEX in the treatment of visceral pain, aiming to provide a foundation and direction for clinical practice and basic research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.